Koers Xtl Biopharma TEL AVIV STOCK EXCHANGE
Aandelen
IL0010854979
Biotechnologie & Medisch Onderzoek
Omzet 2022 | - | Omzet 2023 | - | Marktkapitalisatie | 5,28 mln. 1,91 mld. 4,84 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2022 | -1 mln. -362 mln. -917K | Nettowinst (verlies) 2023 | -1 mln. -362 mln. -917K | EV/omzet 2022 | - |
Nettoliquiditeiten 2022 | 3,72 mln. 1,35 mld. 3,41 mln. | Nettoliquiditeiten 2023 | 2,01 mln. 726 mln. 1,84 mln. | EV/omzet 2023 | - |
K/w-verhouding 2022 |
-4,72
x | K/w-verhouding 2023 |
-2,96
x | Werknemers | - |
Dividendrendement 2022 * |
-
| Dividendrendement 2023 |
-
| Vrij verhandelbaar | 93,3% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Itay Weinstein
DFI | Director of Finance/CFO | 52 | 01-01-99 |
Doron Turgeman
CHM | Chairman | 56 | 30-12-14 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Shlomo Shalev
CEO | Chief Executive Officer | 62 | 30-12-14 |
Director/Board Member | 57 | 29-01-20 | |
Director/Board Member | 53 | 01-04-17 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
+25,83% | 46,56 mld. | |
+45,38% | 41,67 mld. | |
+0,69% | 41,16 mld. | |
+30,52% | 32,4 mld. | |
+22,30% | 28,18 mld. | |
-6,35% | 28,1 mld. | |
+49,25% | 14,52 mld. | |
+49,18% | 13,74 mld. | |
+3,45% | 12,17 mld. |